117 related articles for article (PubMed ID: 23873179)
21. Prothrombin polymorphism A19911G, factor V HR2 haplotype A4070G, and plasminogen activator-inhibitor-1 polymorphism 4G/5G and the risk of retinal vein occlusion.
Kuhli-Hattenbach C; Hellstern P; Nägler DK; Kohnen T; Hattenbach LO
Ophthalmic Genet; 2017; 38(5):413-417. PubMed ID: 28085526
[TBL] [Abstract][Full Text] [Related]
22. GLU298ASP and 4G/5G Polymorphisms and the Risk of Ischemic Stroke in Young Individuals.
Esparza-García JC; Santiago-Germán D; Guadalupe Valades-Mejía M; Hernández-Juárez J; Aguilar-Sosa E; Leaños-Miranda A; Alvarado-Moreno A; Majluf-Cruz A; Isordia-Salas I
Can J Neurol Sci; 2015 Sep; 42(5):310-6. PubMed ID: 26036781
[TBL] [Abstract][Full Text] [Related]
23. Investigation of Plasminogen Activator Inhibitor-1 (PAI-1) 4G/5G promoter polymorphism in Indian venous thrombosis patients: A case-control study.
Prabhudesai A; Shetty S; Ghosh K; Kulkarni B
Eur J Haematol; 2017 Sep; 99(3):249-254. PubMed ID: 28561456
[TBL] [Abstract][Full Text] [Related]
24. Plasminogen activator inhibitor-1 5G/5G genotype is associated with early spontaneous recanalization of the infarct-related artery in patients presenting with acute ST-elevation myocardial infarction.
Cagliyan CE; Yuregir OO; Balli M; Tekin K; Akilli RE; Bozdogan ST; Turkmen S; Deniz A; Baykan OA; Aslan H; Cayli M
Coron Artery Dis; 2013 May; 24(3):196-200. PubMed ID: 23283030
[TBL] [Abstract][Full Text] [Related]
25. Diabetic retinopathy, PAI-1 4G/5G and -844G/A polymorphisms, and changes in circulating PAI-1 levels in Tunisian type 2 diabetes patients.
Ezzidi I; Mtiraoui N; Chaieb M; Kacem M; Mahjoub T; Almawi WY
Diabetes Metab; 2009 Jun; 35(3):214-9. PubMed ID: 19419896
[TBL] [Abstract][Full Text] [Related]
26. Plasminogen activator inhibitor-1 (PAI-1) 4 G/5 G polymorphism and endometrial cancer. Influence of PAI-1 polymorphism on tissue PAI-1 antigen and mRNA expression and tumor severity.
Gilabert-Estellés J; Ramón LA; Braza-Boïls A; Gilabert J; Chirivella M; España F; Estellés A
Thromb Res; 2012 Aug; 130(2):242-7. PubMed ID: 22055623
[TBL] [Abstract][Full Text] [Related]
27. Analysis of -675 4 g/5 G SERPINE1 and C-159T CD14 polymorphisms in house dust mite-allergic asthma patients.
Kowal K; Bodzenta-Lukaszyk A; Pampuch A; Szmitkowski M; Zukowski S; Donati MB; Iacoviello L
J Investig Allergol Clin Immunol; 2008; 18(4):284-92. PubMed ID: 18714537
[TBL] [Abstract][Full Text] [Related]
28. Plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G promoter polymorphism is seen in higher frequency in the Indian patients with deep vein thrombosis.
Akhter MS; Biswas A; Ranjan R; Meena A; Yadav BK; Sharma A; Saxena R
Clin Appl Thromb Hemost; 2010 Apr; 16(2):184-8. PubMed ID: 19419975
[TBL] [Abstract][Full Text] [Related]
29. The Association of Plasminogen Activator Inhibitor Type 1 (PAI-1) Level and PAI-1 4G/5G Gene Polymorphism with the Formation and the Grade of Endometrial Cancer.
Yıldırım ME; Karakuş S; Kurtulgan HK; Kılıçgün H; Erşan S; Bakır S
Biochem Genet; 2017 Aug; 55(4):314-321. PubMed ID: 28303356
[TBL] [Abstract][Full Text] [Related]
30. Genetic polymorphisms at FCER1B and PAI-1 and asthma susceptibility.
Hizawa N; Maeda Y; Konno S; Fukui Y; Takahashi D; Nishimura M
Clin Exp Allergy; 2006 Jul; 36(7):872-6. PubMed ID: 16839401
[TBL] [Abstract][Full Text] [Related]
31. Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity.
Castelló R; España F; Vázquez C; Fuster C; Almenar SM; Aznar J; Estellés A
Thromb Res; 2006; 117(5):487-92. PubMed ID: 15907980
[TBL] [Abstract][Full Text] [Related]
32. Transforming growth factor-beta1 gene polymorphisms associated with chronic obstructive pulmonary disease in Chinese population.
Su ZG; Wen FQ; Feng YL; Xiao M; Wu XL
Acta Pharmacol Sin; 2005 Jun; 26(6):714-20. PubMed ID: 15916738
[TBL] [Abstract][Full Text] [Related]
33. Fibrogenic polymorphisms (TGF-beta, PAI-1, AT) in Mexican patients with established liver fibrosis. Potential correlation with pirfenidone treatment.
Armendáriz-Borunda J; Rincón AR; Muñoz-Valle JF; Bueno-Topete M; Oregón-Romero E; Islas-Carbajal MC; Medina-Preciado D; González-García I; Bautista CA; García-Rocha S; Godoy J; Vázquez-Del Mercado M; Troyo-SanRoman R; Arellano-Olivera I; Lucano S; Alvarez-Rodríguez A; Salazar A
J Investig Med; 2008 Oct; 56(7):944-53. PubMed ID: 18797412
[TBL] [Abstract][Full Text] [Related]
34. Impact of TGF-β1 -509C/T and 869T/C polymorphisms on glioma risk and patient prognosis.
Vieira de Castro J; Gonçalves CS; Costa S; Linhares P; Vaz R; Nabiço R; Amorim J; Viana-Pereira M; Reis RM; Costa BM
Tumour Biol; 2015 Aug; 36(8):6525-32. PubMed ID: 25813152
[TBL] [Abstract][Full Text] [Related]
35. Lack of association between -460 C/T and 936 C/T of the vascular endothelial growth factor and angiopoietin-2 exon 4 G/A polymorphisms and ovarian, cervical, and endometrial cancers.
Konac E; Onen HI; Metindir J; Alp E; Biri AA; Ekmekci A
DNA Cell Biol; 2007 Jul; 26(7):453-63. PubMed ID: 17630849
[TBL] [Abstract][Full Text] [Related]
36. P53 tumor suppressor factor, plasminogen activator inhibitor, and vascular endothelial growth factor gene polymorphisms and recurrent implantation failure.
Goodman C; Jeyendran RS; Coulam CB
Fertil Steril; 2009 Aug; 92(2):494-8. PubMed ID: 18829023
[TBL] [Abstract][Full Text] [Related]
37. Plasminogen activator inhibitor -1 gene 4G/5G polymorphism in patients with breast cancer.
Eroglu A; Ulu A; Cam R; Akar N
J BUON; 2006; 11(4):481-4. PubMed ID: 17309181
[TBL] [Abstract][Full Text] [Related]
38. VEGF polymorphisms in early cervical cancer susceptibility, angiogenesis, and survival.
Kim YH; Kim MA; Park IA; Park WY; Kim JW; Kim SC; Park NH; Song YS; Kang SB
Gynecol Oncol; 2010 Nov; 119(2):232-6. PubMed ID: 20797778
[TBL] [Abstract][Full Text] [Related]
39. PAI-1 haplogenotype confers genetic susceptibility for obesity and hypertriglyceridemia in Mexican children.
de la Cruz-Mosso U; Elena Ramos-Arellano L; Francisco Muñoz-Valle J; Berenice Salgado-Bernabé A; Salgado-Goytia L; Castro-Alarcón N; Ramírez-Peralta A; Parra-Rojas I
Invest Clin; 2016 Sep; 57(3):246-58. PubMed ID: 29938477
[TBL] [Abstract][Full Text] [Related]
40. [Plasminogen activator inhibitor-1 (PAI-1) 4G/5G and angiotensin converting enzyme (ACE) I/D gene polymorphisms and fibrinolytic activity in patients with essential hypertension and dyslipidemia].
Jastrzebska M; Widecka K; Ciechanowicz A; Goracy I; Wesołowska T; Torbus-Lisiecka B; Foltyńska-Nowakowska A; Naruszewicz M
Pol Arch Med Wewn; 2005 Jan; 113(1):7-20. PubMed ID: 16130596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
